1 / 1
Idelalisib(Zydelig)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
Gilead
Formulation:
TABLET
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Zydelig (idelalisib) is an oral, selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), a key enzyme involved in the proliferation, survival, and trafficking of malignant B-cells. By targeting PI3Kδ, idelalisib disrupts critical signaling pathways in B-cell malignancies, leading to apoptosis and inhibition of tumor cell growth. The drug is formulated as film-coated tablets available in 100 mg and 150 mg strengths, and is administered orally, typically at a starting dose of 150 mg twice daily.
Clinically, Zydelig is utilized in the management of specific relapsed hematologic malignancies, particularly in patients who have limited therapeutic options due to prior treatment failures or comorbidities. Its use is associated with significant risks, including hepatotoxicity, severe diarrhea or colitis, pneumonitis, and intestinal perforation, necessitating careful patient selection, close monitoring, and adherence to recommended dose modifications. The safety profile and efficacy in populations outside the specified indications, such as pediatric patients or those with significant hepatic impairment, remain unestablished (not specified in the specification).
